Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase III trial of Fintepla in Lennox-Gastaut syndrome meets primary endpoint

Feb. 7, 2020

AVN-576 shows promise in rat models of TBI

Feb. 7, 2020

Karuna Therapeutics updates research and discovery efforts in CNS

Feb. 7, 2020

Cav3.2 blockers patented by Nippon Chemiphar and Kindai University

Feb. 7, 2020

Tonix stops enrollment in phase III PTSD study of Tonmya for futility

Feb. 6, 2020

Phase IIb study of SAR-442168 in relapsing MS meets primary endpoint

Feb. 6, 2020

Pfizer identifies new monoglyceride lipase inhibitors

Feb. 6, 2020

Rodin Therapeutics identifies new HDAC inhibitors

Feb. 6, 2020

Gedeon Richter patents alpha-7 nicotinic receptor positive allosteric modulators

Feb. 6, 2020

From African genomes, big insights with small sample size

Feb. 6, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...